Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (12), 1457-1463

Malignancy Incidences by Glycemic Control Among Diabetic Patients


Malignancy Incidences by Glycemic Control Among Diabetic Patients

Daiki Kobayashi et al. Endocr Connect.


Background: The aim of this study was to evaluate the difference in malignancy incidence by evaluating time-dependent HbA1c levels among diabetic patients in a longitudinal study.

Methods: We conducted a retrospective longitudinal study at large academic hospital, Tokyo, Japan, from 2006 to 2016. We included all diabetic patients who were 50 years or older and who underwent health check-ups at the Center for Preventive Medicine. Those patients with a prior history of malignancies were excluded. We categorized patients into five groups on the basis of HbA1c measurements: <5.4, 5.5-6.4, 6.5-7.4, 7.5-8.5, >8.5%. Our primary outcome was the development of any types of malignancy. Longitudinal analyses by a mixed effect model with time-dependent HbA1c levels were applied in order to take into account fluctuations in HbA1c levels within the same patient.

Results: In total, 2729 participants were included in this study, where the mean age was 62.6 (standard deviation (s.d.): 7.8) and 2031 (74.4%) were male. The mean disease duration of diabetes was 7.6 (s.d.: 7.6) years, and 1688 (61.8%) were prescribed medications. Median follow-up was 1443.5 (interquartile range (IQR): 2508) days and 376 (13.8%) developed malignancies. Compared to the reference range of HbA1c (5.5-6.4%), the odds ratios for developing malignancies among the other HbA1c level groups were similar and not statistically different (OR: 0.98, 95% CI:0.31-3.15 (for HbA1c <5.4%); OR: 0.88, 95% CI: 0.69-1.12 (for HbA1c 6.5-7.4%); OR: 0.88, 95% CI: 0.64-1.22 (for HbA1c 7.5-8.4%); OR 1.07, 95% CI: 0.70-1.66 (for HbA1c >8.5%)).

Conclusion: In our study, there was no association between glycemic control and the development of future malignancies. Compared to very strictly controlled HbA1c levels, both excessive control and good or bad control had a statistically similar risk of developing malignancies.

Keywords: diabetes; glycemic control; longitudinal analysis; malignancy.

Similar articles

See all similar articles


    1. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015. 350 g7607 (10.1136/bmj.g7607) - DOI - PubMed
    1. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocrine Practice 2011. 17 616–628. (10.4158/EP10357.RA) - DOI - PubMed
    1. Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, Tsuji I, Sugawara Y, Tamakoshi A, Matsuo K, et al Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Science 2013. 104 1499–1507. (10.1111/cas.12241) - DOI - PubMed
    1. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Science 2013. 104 9–14. (10.1111/cas.12043) - DOI - PubMed
    1. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer 2012. 130 1639–1648. (10.1002/ijc.26165) - DOI - PubMed

LinkOut - more resources